

Figure 5

A

Drug	Associated model parameter	Targets	Associated genomic alterations	
OSI-906	k ERK,RSKp90	IGF1R	MYC->PDK1,SMAD2	
OSI-906	k MEK,ERK	IGF1R	MYC->PDK1,SMAD2	
BMS-345541	τ cJun	IKBKB	PARK2-IcJun; MYC->PDK1,SMAD2	
HG-5-88-01	k IKK,ERK	EGFR		
OSI-906	τ RPS6	IGF1R	MYC->PDK1,SMAD2	
BMS-345541	k EGFR,PI3K	IKBKB	PARK2-IcJun; MYC->PDK1,SMAD2	
SB590885	τ IkBa	BRAF		
AZD6244	τ GSK3	MEK		
HG-5-88-01	k MEK,ERK	EGFR		
PD-0325901	k IKK,ERK	MEK		
HG-5-88-01	k ERK,RSKp90	EGFR		
BMS-754807	τ RPS6	IGF1R	MYC->PDK1,SMAD2	
SB590885	k ERK,RPS6	BRAF		
(5Z)-7-Oxozeaenol	k IKK,TBK1	MAP3K7 (TAK1)		
BMS-345541	k PI3K,PAK1	IKBKB	PARK2-IcJun; MYC->PDK1,SMAD2	
AZD6244	k IKK,ERK	MEK		
AZD6244	k RSKp90,GSK3	MEK		
(5Z)-7-Oxozeaenol	k TGFRb,SMAD2	MAP3K7 (TAK1)		
RDEA119	k IKK,ERK	MEK		
RDEA119	k TGFRb,SMAD2	MEK		
(5Z)-7-Oxozeaenol	k MP2K4,JNK	MAP3K7 (TAK1)		
Dabrafenib	k ERK,RPS6	BRAF		
THZ-2-102-1	τ cJun	CDK7->MEK,PAK1	MYC->PDK1,SMAD2	
RDEA119	τ GSK3	MEK		
HG-5-88-01	k ERK,RPS6	EGFR		
SB590885	k RSKp90,GSK3	BRAF		
Afatinib	τ ERK	EGFR; ERBB2->EGFR,SHC1,PI3K,GRB2,PAK1	MYC->PDK1,SMAD2	
(5Z)-7-Oxozeaenol	k PI3K,S6K	MAP3K7 (TAK1)		
Dabrafenib	k TGFRb,SMAD2	BRAF		
BMS-345541	τ mTOR	IKBKB	PARK2-IcJun; MYC->PDK1,SMAD2	
BMS-345541	k EGFR,TGFRb	IKBKB	PARK2-IcJun; MYC->PDK1,SMAD2	
PD-0325901	k ERK,RPS6	MEK		
BMS-345541	τ RPS6	IKBKB	PARK2-IcJun; MYC->PDK1,SMAD2	
(5Z)-7-Oxozeaenol	τ EGFR	MAP3K7 (TAK1)		
PD-0325901	k AKT,GSK3	MEK		
CI-1040	k PI3K,S6K	MEK		
HG-5-88-01	k ERK,BRAF	EGFR		
(5Z)-7-Oxozeaenol	k TAK1,JNK	MAP3K7 (TAK1)		
Afatinib	τ RPS6	EGFR; ERBB2->EGFR,SHC1,PI3K,GRB2,PAK1	MYC->PDK1,SMAD2	
PD-0325901	k PI3K,S6K	MEK		
Dabrafenib	k PI3K,AKT	BRAF		
BMS-345541	k EGF,EGFR	IKBKB	PARK2-IcJun; MYC->PDK1,SMAD2	
Trametinib	k IKK,ERK	MEK		
RDEA119	k IKK,IkBa	MEK		
BMS-345541	k AKT,PAK1	IKBKB	PARK2-IcJun; MYC->PDK1,SMAD2	
AZD6244	k AKT,GSK3	MEK		
AZD6244	τ mTOR	MEK		
SB590885	k ERK,BRAF	BRAF		
PD-0325901	τ IkBa	MEK		
Trametinib	k TGFRb,SMAD2	MEK		

B

